Skip to main content
Erschienen in: Diabetology International 4/2016

31.08.2016 | Commentary

What is the truth about renin angiotensin blockers for diabetic patients?

verfasst von: Atsuko Abiko

Erschienen in: Diabetology International | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Excerpt

Many type 2 diabetic patients have concomitant hypertension. These patients require treatment to maintain their blood pressure (BP) within acceptable ranges to decrease the risk of cardiovascular disease or diabetic nephropathy. Lowering BP can decrease the risk or slow the progression of diabetic nephropathy, and thus it is important to evaluate diabetic patients with albuminuria and perform proper staging of diabetic nephropathy. In the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study in 2009 [1], of 11,140 patients with type 2 diabetes, those who achieved lower BP presented fewer renal events. …
Literatur
1.
Zurück zum Zitat de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, Harrap S, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Glasziou P, Grobbee DE, MacMahon S, Chalmers J, ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883–92.CrossRefPubMedPubMedCentral de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, Harrap S, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Glasziou P, Grobbee DE, MacMahon S, Chalmers J, ADVANCE Collaborative Group. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883–92.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat The Japanese Diabetes Society. Guideline for the Treatment for Diabetes in Japan 2016. Nankodo Co., Ltd., Tokyo; 2016 (Japanese). The Japanese Diabetes Society. Guideline for the Treatment for Diabetes in Japan 2016. Nankodo Co., Ltd., Tokyo; 2016 (Japanese).
3.
Zurück zum Zitat The Japanese Society of Hypertension. Guideline for the management of hypertension 2014. Life Science Publishing Co., Ltd., Tokyo; 2014 (Japanese). The Japanese Society of Hypertension. Guideline for the management of hypertension 2014. Life Science Publishing Co., Ltd., Tokyo; 2014 (Japanese).
4.
Zurück zum Zitat American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2016;39(Suppl. 1):S60–71. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2016;39(Suppl. 1):S60–71.
5.
Zurück zum Zitat ACCORD Study Group. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood–pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575–85. ACCORD Study Group. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood–pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575–85.
6.
Zurück zum Zitat Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K. Yusuf S; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74–83.CrossRefPubMed Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K. Yusuf S; ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74–83.CrossRefPubMed
7.
Zurück zum Zitat Edmin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes A systematic review and meta-analysis. JAMA. 2015;313:603–15.CrossRef Edmin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes A systematic review and meta-analysis. JAMA. 2015;313:603–15.CrossRef
8.
Zurück zum Zitat Bangalore S, fakheri R, Toklu B, messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systemic review and meta-analysis of randomizes trials. BMJ. 2016; 352:i438. doi:10.1136/bmj.i438. Bangalore S, fakheri R, Toklu B, messerli FH. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systemic review and meta-analysis of randomizes trials. BMJ. 2016; 352:i438. doi:10.​1136/​bmj.​i438.
9.
Zurück zum Zitat Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.CrossRefPubMed Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289:2560–72.CrossRefPubMed
10.
Zurück zum Zitat Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med. 2005;165:1401–9.CrossRefPubMed Whelton PK, Barzilay J, Cushman WC, Davis BR, Iiamathi E, Kostis JB, Leenen FH, Louis GT, Margolis KL, Mathis DE, Moloo J, Nwachuku C, Panebianco D, Parish DC, Pressel S, Simmons DL, Thadani U, ALLHAT Collaborative Research Group. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med. 2005;165:1401–9.CrossRefPubMed
11.
Zurück zum Zitat Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.CrossRefPubMed
12.
Zurück zum Zitat Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–56.CrossRefPubMed Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015;385:2047–56.CrossRefPubMed
13.
Zurück zum Zitat Wu H-Y, Huang J-W, Lin H-J, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ. 2013;347:f6008.CrossRefPubMedPubMedCentral Wu H-Y, Huang J-W, Lin H-J, Liao WC, Peng YS, Hung KY, Wu KD, Tu YK, Chien KL. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ. 2013;347:f6008.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821–35.CrossRefPubMed Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, de Zeeuw D, Cheung AK, Coresh J. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821–35.CrossRefPubMed
15.
Zurück zum Zitat Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the US continues to decline. Diabetes Care. 2010;33:73–7.CrossRefPubMedPubMedCentral Burrows NR, Li Y, Geiss LS. Incidence of treatment for end-stage renal disease among individuals with diabetes in the US continues to decline. Diabetes Care. 2010;33:73–7.CrossRefPubMedPubMedCentral
Metadaten
Titel
What is the truth about renin angiotensin blockers for diabetic patients?
verfasst von
Atsuko Abiko
Publikationsdatum
31.08.2016
Verlag
Springer Japan
Erschienen in
Diabetology International / Ausgabe 4/2016
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-016-0285-8

Weitere Artikel der Ausgabe 4/2016

Diabetology International 4/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.